TSE:3407
TSE:3407Chemicals

Asahi Kasei (TSE:3407) Valuation in Focus After KDIGO Nefecon Win and High-Power Battery Deal

Asahi Kasei (TSE:3407) shares have seen renewed investor focus after two recent developments. Most notably, the company’s Nefecon gained inclusion in the KDIGO 2025 guidelines for IgA nephropathy, which bolsters its presence in the pharmaceutical sector. See our latest analysis for Asahi Kasei. Asahi Kasei’s share price momentum has picked up, climbing 9.6% over the last three months as investors reacted positively to both the KDIGO guideline inclusion for Nefecon and the company’s push into...
TSE:3401
TSE:3401Chemicals

Teijin (TSE:3401): Examining Valuation After Recent Share Price Momentum

Teijin (TSE:3401) has kept investors interested with its recent stock performance, especially over the past month. Shares have climbed nearly 5% during this period, even in spite of slight dips seen over the past week. See our latest analysis for Teijin. Teijin’s 1-month share price return of nearly 5% stands out against a more modest year-to-date climb and recent weekly softness. This suggests fresh momentum may be building. Looking at the bigger picture, the 3-year total shareholder return...
TSE:6201
TSE:6201Machinery

Toyota Industries (TSE:6201): Valuation in Focus After Earnings Cut and Dividend Suspension

Toyota Industries (TSE:6201) just announced a downward revision to its full-year earnings forecast, largely driven by costs from a U.S. class-action lawsuit and new tariffs. The company also suspended its interim dividend. See our latest analysis for Toyota Industries. Toyota Industries’ surprise earnings cut and dividend suspension followed a year of strong positive momentum, with the 1-year total shareholder return still an impressive 61.8%. While recent headline risks sparked some nerves,...
TSE:2802
TSE:2802Food

What Ajinomoto (TSE:2802)'s ADC Technology Licensing Deal With Astellas Means For Shareholders

In late October 2025, Astellas Pharma announced it has signed a licensing agreement with Ajinomoto Co., Inc. to utilize Ajinomoto's AJICAP antibody-drug conjugate (ADC) technology in its contract development and manufacturing operations for biopharmaceuticals. This partnership underscores Ajinomoto's expanding capabilities in the biopharma sector, as it leverages its proprietary technology to support the development of innovative next-generation treatments for patients. We'll examine how...
TSE:6920
TSE:6920Semiconductor

Lasertec (TSE:6920): Reviewing Valuation After New 2026 Financial Projections Boost Investor Optimism

Lasertec (TSE:6920) just released its financial projections for the year ending June 2026, giving investors an early look at what the company expects in terms of revenue and profitability for the coming period. See our latest analysis for Lasertec. Lasertec’s latest guidance sparked strong momentum, with the 1-week share price return hitting an impressive 40.6% and a 30-day return of 53.8% as investors digested upbeat forecasts and the recently announced share buyback proposal. Looking at the...